Pepper Bio’s Post

Scientists from the Wellcome Sanger Institute, who used machine learning to identify 370 drug targets across 27 types of cancer, say their discovery will help drug developers focus their efforts on the highest value targets to bring new medicines to patients more quickly. They note the biomarkers associated with the targets increases 2- to 4-fold the probability of FDA approval of a drug during clinical development. I agree with Fierce’s takeaway—that this research suggests multiomics biomarker tests could help expand therapy targets in patients. #multiomics #oncology 

🚀 Exciting Breakthrough in Liver Cancer Treatment! 🚀 Pepper Bio's AI-driven platform, COMPASS, has made a significant discovery in the fight against liver cancer. By integrating various omics data, they've identified lerociclib, a CDK4/6 inhibitor, showing great promise in preclinical tests for MYC-driven hepatocellular carcinoma (HCC). This advancement led to a substantial licensing deal worth $100 million, potentially transforming treatment options for a challenging and heterogeneous disease. Read more about this groundbreaking research: https://lnkd.in/eX6MyH3U #LiverCancer #Biotech #AI #HealthcareInnovation #Transomics #MedicalResearch

"A new artificial intelligence (AI) tool that can help physicians to select the most suitable treatment for cancer patients has been developed by researchers at The Australian National University (ANU). DeepPT, developed in collaboration with scientists at the National Cancer Institute in America and pharmaceutical company Pangea Biomed, works by predicting a patient's messenger RNA (mRNA) profile. This mRNA—essential for protein production—is also the key molecular information for personalized cancer medicine." #ai #cancer #oncology #cancertherapy

New EditCo Bio publication hot off the press! Learn how we're carving a path for potential "off-the-shelf" CAR-T therapies.📰🔥 In collaboration with the University of Wisconsin-Madison and Synthego Corporation, our new ground-breaking publication shows how multiplex editing and large non-viral DNA insertions may be the solution to prior challenges with CAR-T, especially for solid tumors. So exciting to see how precision CRISPR tools and the expertise to optimize novel editing strategies will have huge implications for future cancer therapies. Read the article here: https://hubs.la/Q02z66R20 #CARTtherapies #oncology #CRISPR #EditCoBio

𝐍𝐞𝐰 𝐟𝐫𝐨𝐦 EditCo Bio: 𝐀 𝐒𝐭𝐞𝐩 𝐅𝐨𝐫𝐰𝐚𝐫𝐝 𝐢𝐧 𝐂𝐀𝐑-𝐓 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 We are deeply honored to share our latest research milestone, achieved in collaboration with the University of Wisconsin-Madison and Synthego Corporation. Our 𝐧𝐞𝐰 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 highlights the potential of 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞𝐱 𝐞𝐝𝐢𝐭𝐢𝐧𝐠 and 𝐥𝐚𝐫𝐠𝐞 𝐧𝐨𝐧-𝐯𝐢𝐫𝐚𝐥 𝐃𝐍𝐀 𝐢𝐧𝐬𝐞𝐫𝐭𝐢𝐨𝐧𝐬 to address previous challenges in 𝐂𝐀𝐑-𝐓 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, especially for 𝐬𝐨𝐥𝐢𝐝 𝐭𝐮𝐦𝐨𝐫𝐬. This work represents a 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐚𝐝𝐯𝐚𝐧𝐜𝐞, driven by the precision of 𝐂𝐑𝐈𝐒𝐏𝐑 𝐭𝐨𝐨𝐥𝐬 and 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐞𝐝𝐢𝐭𝐢𝐧𝐠 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬. While there is still much work to be done, this research offers a 𝒑𝒓𝒐𝒎𝒊𝒔𝒊𝒏𝒈 𝒂𝒗𝒆𝒏𝒖𝒆 𝒇𝒐𝒓 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒊𝒏𝒈 𝒎𝒐𝒓𝒆 𝒆𝒇𝒇𝒆𝒄𝒕𝒊𝒗𝒆 𝒂𝒏𝒅 𝒂𝒄𝒄𝒆𝒔𝒔𝒊𝒃𝒍𝒆 𝑪𝑨𝑹-𝑻 𝒕𝒉𝒆𝒓𝒂𝒑𝒊𝒆𝒔. Our 𝐠𝐨𝐚𝐥 is to 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐞 to the 𝐨𝐧𝐠𝐨𝐢𝐧𝐠 𝐟𝐢𝐠𝐡𝐭 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 by 𝐢𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 the 𝐭𝐨𝐨𝐥𝐬 and 𝐭𝐞𝐜𝐡𝐧𝐢𝐪𝐮𝐞𝐬 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 to 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 and 𝐜𝐥𝐢𝐧𝐢𝐜𝐢𝐚𝐧𝐬. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞: 👉 https://hubs.la/Q02z66R20 #CARTtherapies #CART #CGT #Immunotherapy #Oncology #CRISPR #EditCoBio

Science and health research is moving towards new advances

Precision in Action: Genprex's Acclaim Trials and the Path to Personalized Lung Cancer Treatment Acclaim-1, Acclaim-2, and Acclaim-3 — these aren't just trials; they're milestones in the evolution of lung cancer treatment. Genprex, Inc.'s commitment to precision is evident in these trials, promising not just treatments but tailored solutions for patients. 🎯 In this recent article, by Angela Scott-Briggs of TechBullion, we explore the significance of the Acclaim series. Read more about it here: https://lnkd.in/gzsWMjAb #Genprex #AcclaimTrials #biotech #innovation

#TrendingWithImpact: On February 5, 2024, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson from ONCOtherapeutics, Berenson Cancer Center, and Institute for Myeloma and Bone Cancer Research published a new research perspective in Oncotarget, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.” “[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.” #PressRelease: https://lnkd.in/efA4dhzy #cancerresearch #multiplemyeloma #cytokines #clinicaltrials #oncology #openaccess #openscience #peerreviewed #publication #publishing #meded

Oncogenic transcription factors instruct promoter-enhancer hubs in individual triple negative breast cancer cells Science Advances https://lnkd.in/gvTyAdc2

#Bacteriophages are emerging as a promising solution for cancer therapy. Discover the ongoing research and future potential of bacteriophages in delivering genes and drugs in #cancertherapy. Read more in our latest blog. https://lnkd.in/ekcqM2e7